Syneos Health (Nasdaq:SYNH) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

SYNH Panoramica delle azioni

Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company.

SYNH analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	3/6
Prestazioni passate	1/6
Salute finanziaria	3/6
Dividendi	0/6

Premi

Negoziato a 25.3% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 33.7% all'anno

Analisi del rischio

Il debito non è ben coperto dal flusso di cassa operativo

Grandi elementi una tantum che incidono sui risultati finanziari

I margini di profitto (1.3%) sono inferiori rispetto allo scorso anno (5.1%)

Syneos Health, Inc. Concorrenti

Sotera Health

NasdaqGS:SHC

US$4.2b

Stevanato Group

NYSE:STVN

US$5.3b

Bruker

NasdaqGS:BRKR

US$9.9b

Charles River Laboratories International

NYSE:CRL

US$10.5b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Syneos Health
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$42.98
Massimo di 52 settimane	US$52.23
Minimo di 52 settimane	US$22.89
Beta	1.58
1Variazione di 1 mese	0.66%
Variazione a 3 mesi	1.99%
Variazione di 1 anno	-8.84%
3Variazione a 3 anni	-23.06%
Variazione a 5 anni	-10.61%
Variazione dall'IPO	109.76%

Notizie e aggiornamenti recenti

Recent updates

Is There An Opportunity With Syneos Health, Inc.'s (NASDAQ:SYNH) 49% Undervaluation?

Jun 18

Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Jun 03

We Think Syneos Health (NASDAQ:SYNH) Can Stay On Top Of Its Debt

May 19

Do Syneos Health's (NASDAQ:SYNH) Earnings Warrant Your Attention?

Apr 08

Syneos Health: Upside Opportunity After Unexpected Correction In CRO Market, M&A Rumors

Mar 27

Is Now An Opportune Moment To Examine Syneos Health, Inc. (NASDAQ:SYNH)?

Mar 05

Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Feb 18

Are Investors Undervaluing Syneos Health, Inc. (NASDAQ:SYNH) By 39%?

Feb 03

With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Is Interesting

Jan 04

Syneos Health's Double-Digit Revenue Growth Sets The Tone For A Strong 2022

Dec 03

Is It Too Late To Consider Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Dec 03

Rendimenti per gli azionisti

	SYNH	US Life Sciences	US Mercato
7D	0.6%	1.8%	3.1%
1Y	-8.8%	7.6%	25.4%

Ritorno vs Industria: SYNH ha superato il US Life Sciences che ha restituito 7.1 % nell'ultimo anno.

Rendimento vs Mercato: SYNH ha avuto una performance inferiore al mercato US che ha registrato un rendimento 25.6 % nell'ultimo anno.

Volatilità dei prezzi

Is SYNH's price volatile compared to industry and market?
SYNH volatility
SYNH Average Weekly Movement	0.3%
Life Sciences Industry Average Movement	8.6%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.2%

Prezzo delle azioni stabile: SYNH non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di SYNH è diminuita da 9% a 0% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2010	28,768	Michelle Keefe	www.syneoshealth.com

Syneos Health, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Syneos Health con la sua capitalizzazione di mercato?
SYNH statistiche fondamentali
Capitalizzazione di mercato	US$4.46b
Guadagni(TTM)	US$71.22m
Ricavi(TTM)	US$5.42b

62.6x

Rapporto P/E

0.8x

Rapporto P/S

SYNH è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
SYNH Conto economico (TTM)
Ricavi	US$5.42b
Costo del fatturato	US$4.22b
Profitto lordo	US$1.20b
Altre spese	US$1.13b
Guadagni	US$71.22m

Ultimi guadagni dichiarati

Jun 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	0.69
Margine lordo	22.14%
Margine di profitto netto	1.31%
Rapporto debito/patrimonio netto	75.8%

Come si è comportato SYNH nel lungo periodo?

Vedi performance storica e confronto

SYNH Panoramica delle azioni

Premi

Analisi del rischio

Syneos Health, Inc. Concorrenti

NasdaqGS:SHC

US$4.2b

NYSE:STVN

US$5.3b

NasdaqGS:BRKR

US$9.9b

NYSE:CRL

US$10.5b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Syneos Health Files Form 15

Syneos Health, Inc. Announces Chief Executive Officer Changes

Syneos Health, Inc. Announces Management Changes

Patient Square Capital, LP, Elliott Investment Management L.P. and Veritas Capital Fund Management, L.L.C completed the acquisition of Syneos Health, Inc. (NasdaqGS:SYNH) from a group of shareholders.

Syneos Health Names Terttu Haring President, Clinical Sites & Patients

Levi & Korsinsky Notifies Syneos Health, Inc. Investors of A Class Action Lawsuit and Upcoming Deadline

Recent updates

Syneos Health Files Form 15

Syneos Health, Inc. Announces Chief Executive Officer Changes

Syneos Health, Inc. Announces Management Changes

Patient Square Capital, LP, Elliott Investment Management L.P. and Veritas Capital Fund Management, L.L.C completed the acquisition of Syneos Health, Inc. (NasdaqGS:SYNH) from a group of shareholders.

Syneos Health Names Terttu Haring President, Clinical Sites & Patients

Levi & Korsinsky Notifies Syneos Health, Inc. Investors of A Class Action Lawsuit and Upcoming Deadline

Consensus EPS estimates fall by 70%

The Klein Law Firm Announces That a Class Action Complaint Has Been Filed on Behalf of Shareholders of Syneos Health, Inc

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Syneos Health, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Syneos Health, Inc

Syneos Health Appoints Hillary Bochniak as Chief Human Resources Officer

Syneos Health, Inc. Appoints Batisha Anson to Global Head, Patient Diversity and Health Equity

Consensus EPS estimates fall from profit to US$0.31 loss, revenue upgraded

Patient Square Capital, LP, Elliott Investment Management L.P. and Veritas Capital Fund Management, L.L.C entered into an agreement to acquire Syneos Health, Inc. (NasdaqGS:SYNH) in a transaction valued at approximately $7.5 billion.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 17%

Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Does Syneos Health (NASDAQ:SYNH) Have A Healthy Balance Sheet?

Is Syneos Health, Inc. (NASDAQ:SYNH) Trading At A 40% Discount?

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Syneos Health, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Consensus EPS estimates fall by 11%

Price target decreased by 10% to US$36.95

Syneos Health, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Syneos Health, Inc. Reaffirms Revenue Guidance for the Full Year 2022

Should You Investigate Syneos Health, Inc. (NASDAQ:SYNH) At US$34.33?

Is Syneos Health (NASDAQ:SYNH) Using Too Much Debt?

High number of new directors

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Syneos Health, Inc. Revises Earnings Guidance for the Fiscal Year 2022

Here's Why Syneos Health (NASDAQ:SYNH) Has Caught The Eye Of Investors

Syneos Health Adds Hub Patient Suite to Deployment Solutions Business

Syneos Health, Inc. to Report Q3, 2022 Results on Nov 04, 2022

Syneos Health, Inc. Announces Executive Changes

Price target decreased to US$69.73

Syneos, Datavant expand partnership on data analytics for clinical trials

Investor sentiment deteriorated over the past week

Syneos Health falls 13% after update on outlook

When Should You Buy Syneos Health, Inc. (NASDAQ:SYNH)?

Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Syneos Health, Inc. (NasdaqGS:SYNH) acquired Boco Digital Media, LLC.

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Syneos Health, Inc. Provides Earnings Guidance for the Third Quarter of 2022

Syneos Health Q2 2022 Earnings Preview

With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Makes An Interesting Case

Syneos Health, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Syneos: Upside Could Be Priced In, Valuations Unsupportive

Is There An Opportunity With Syneos Health, Inc.'s (NASDAQ:SYNH) 49% Undervaluation?

Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

We Think Syneos Health (NASDAQ:SYNH) Can Stay On Top Of Its Debt

Consensus forecasts updated

High number of new directors

Syneos Health, Inc. Revises Earnings Guidance for the Fiscal Year 2022

First quarter 2022 earnings: EPS misses analyst expectations

Syneos Health Announces Executive Promotions

Syneos Health, Inc., Annual General Meeting, May 25, 2022

Syneos Health, Inc. to Report Q1, 2022 Results on Apr 29, 2022